FORE Biotherapeutics to Participate in Upcoming Investor Conferences

01 Feb 2024
www.businesswire.com
Phase 2Clinical ResultPhase 1
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced that the Company, will participate at the following investor conferences:
Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will take place on Wednesday, February 14 from 8:00 a.m. - 8:30 a.m. ET
Evercore ISI’s 2024 Emerging Private Biotech Conference. The presentation will take place on Wednesday, February 28 from 1:05 p.m. – 1:35 p.m. ET
Shawn M. Leland, PharmD, RPh, Interim Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; PLX8394) is an inhibitor of BRAF dimerization allowing for the targeting of V600 and non-V600 driven tumors. In Phase 1/2a, plixorafenib demonstrated deep and durable responses in V600-mutated MAPK inhibitor-naïve patients, including a 42% overall response in patients with solid tumors with a median duration of response of 17.8 months and a 67% overall response rate in patients with primary central nervous system tumors with a median duration of response of 13.9 months. Plixorafenib is currently being investigated in the ongoing, potentially registrational Phase 2 FORTE study. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.